| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | a2M |
| Uniprot No | P01023 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 641-730aa |
| 氨基酸序列 | DCINRHNVYINGITYTPVSSTNEKDMYSFLEDMGLKAFTNSKIRKPKMCP QLQQYEMHGPEGLRVGFYESDVMGRGHARLVHVEEPHTET |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于a2M(α2-巨球蛋白)重组蛋白的3篇文献示例(虚构内容，仅供格式参考)：
1. **文献名称**：*Recombinant α2-Macroglobulin Expression in HEK293 Cells and Its Role in Inhibiting Neurodegeneration*
**作者**：Smith J, et al.
**摘要**：研究通过HEK293细胞高效表达重组a2M蛋白，并验证其通过捕获淀粉样蛋白β抑制神经元凋亡的能力，为阿尔茨海默病治疗提供新策略。
2. **文献名称**：*Structural and Functional Analysis of Engineered α2-Macroglobulin with Enhanced Protease Trapping Capacity*
**作者**：Lee H, et al.
**摘要**：通过基因改造优化重组a2M的“诱捕”结构域，显著提高其对基质金属蛋白酶(MMPs)的抑制活性，为炎症性疾病治疗提供潜在工具。
3. **文献名称**：*A Novel Bacterial Expression System for Cost-effective Production of Functional α2-Macroglobulin*
**作者**：Zhang Y, et al.
**摘要**：开发基于大肠杆菌的重组a2M表达纯化体系，解决了传统哺乳动物系统成本高的问题，并验证其与天然蛋白相似的免疫调节功能。
如需真实文献，建议通过PubMed或Google Scholar检索关键词“recombinant alpha-2-macroglobulin”获取。
**Background of Recombinant α2-Macroglobulin (a2M)**
α2-Macroglobulin (a2M) is a large, evolutionarily conserved plasma glycoprotein belonging to the protease inhibitor family. It plays a critical role in regulating protease activity, immune responses, and cellular signaling. Native a2M is a tetrameric protein composed of four identical subunits, each containing a unique "bait region" that lures proteases. Upon protease cleavage, a2M undergoes a conformational change, entrapping the protease in a mechanism termed "protease trapping." This inhibits the protease’s activity and targets the complex for clearance via receptor-mediated endocytosis, primarily through the low-density lipoprotein receptor-related protein 1 (LRP1).
Beyond protease inhibition, a2M interacts with cytokines, growth factors, and pathogens, functioning as a carrier or scavenger. Its involvement in modulating inflammation, tissue repair, and cellular homeostasis has spurred interest in therapeutic applications. Recombinant a2M (ra2M), produced via genetic engineering in systems like mammalian cells or bacteria, retains these biological properties while offering scalability and purity for clinical use.
Research highlights ra2M’s potential in treating neurodegenerative diseases (e.g., Alzheimer’s), inflammatory disorders, and cancer. Its ability to neutralize excess proteases in pathological conditions, such as matrix metalloproteinases (MMPs) in osteoarthritis, underscores its therapeutic promise. Additionally, ra2M’s role in enhancing stem cell survival and promoting tissue regeneration is being explored. Challenges remain in optimizing its stability, delivery, and specificity, but advancements in recombinant technology continue to drive its translational potential.
×
